ImmuneResearch Phase

LL-37

Subcutaneous injection, Topical

Overview

The only human cathelicidin antimicrobial peptide, a 37-amino acid cationic peptide cleaved from the precursor protein hCAP18. LL-37 disrupts microbial membranes through electrostatic interactions and exerts broad-spectrum activity against bacteria, fungi, and enveloped viruses.

Mechanism of Action

Beyond direct antimicrobial effects, it modulates innate immunity by recruiting immune cells, promoting angiogenesis, and regulating inflammatory cytokine release..

Research Summary & Key Findings

Demonstrated broad-spectrum antimicrobial activity against antibiotic-resistant organisms including MRSA. Plays a role in wound healing and immune defense at epithelial surfaces. Dysregulation implicated in rosacea (overexpression) and chronic wounds (deficiency). Research suggests therapeutic potential in chronic infections and wound healing.

Clinical Status

Research Phase

LL-37 is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.

Administration Routes

Subcutaneous injectionTopical

Related Peptides in Immune

Find a Provider

Find a verified provider who offers LL-37 therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply LL-37.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.